Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Validation of Molecular Biomarkers for the Early Detection of Lung Cancer in the setting of Indeterminate Pulmonary Nodules (Lung Team Project #2)
Team Project

Validation of Molecular Biomarkers for the Early Detection of Lung Cancer in the setting of Indeterminate Pulmonary Nodules (Lung Team Project #2)

354
Spira, AvrumBoston University
Feng, ZidingFred Hutchinson Cancer Research Center

No involved investigator sites defined.

1) a multi-gene mRNA biomarker measured in cytologically normal large airway epithelial cells identified using genome-wide gene-expression profiling, 2) proteomic profiles measured in bronchial airway epithelial cells, 3) serum glycan antibody signature, 4) hypermethylated sites found in promoter regions of tumor suppressor genes measured in blood, 5) cytokines and growth factors secreted from the tumor microenvironment measured in peripheral blood, and 6) two distinct circulating miRNA signatures measured in the serum and plasma
Proteomics
Lung and Upper Aerodigestive Cancers Research Group
2

To characterize intra or within subject reproducibility and variability To characterize inter or across subject variability by adenoma phenotype (normal vs. adenoma) To evaluate biomarker expression in relation to long term adenoma recurrence

3.1.1   Aim 1 Establish a cohort (n=200) of current and former smokers with indeterminate pulmonary nodules (7mm-25mm) on whom clinical, radiographic and biospecimen repositories are developed and who are followed prospectively until final diagnosis. 3.1.2   Aim 2 Validate the diagnostic accuracy of existing molecular biomarkers in the airway and blood to detect lung cancer in this clinical cohort.
Airway gene-expression biomarker (BU) Airway protein biomarker (VU): LC-MRM-MS analyses Serum glycan biomarker (NYU): Plasma promoter methylation biomarker (JHU): Serum cytokines biomarker (UCLA): Serum/Plasma miRNA biomarker (OSU): Plasma miRNA biomarker (UMD):

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


Announcement 04/26/2017

A new funding opportunity associated with the Beau Biden Cancer Moonshot Initiative, Integration and Validation of Emerging Technologies to Accelerate Cancer Research, has been released and is due May 10, 2017. Click here for more information.

Announcement 03/14/2017

Thank you to everyone who made the March 2017 EDRN Steering Committee Meeting a success. The next EDRN Steering Committee Meeting will be on September 12-14, 2017, in Seattle, WA.

EDRN Founder Honored

Dr. Sudhir Srivastava was honored with the Distinguished Service Award from the American Pancreatic Association at the group's annual meeting this year, for his outstanding commitment to pancreatology.